Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats hypertension. Sold as Cardene, Cardene In 4.8% Dextrose In Plastic Container, Cardene In 0.86% Sodium Chloride In Plastic Container, Cardene In 0.83% Sodium Chloride In Plastic Container, Cardene In 5.0% Dextrose In Plastic Container and 3 more. Every FDA application for this active ingredient: 5 branded and 25 generic.
As of Nov 22, 2026, FDA lists 30 applications for Nicardipine hydrochloride (sold as Cardene, Cardene In 4.8% Dextrose In Plastic Container, Cardene In 0.86% Sodium Chloride In Plastic Container and others), first approved Dec 21, 1988, with 0 new uses approved and 0 published complete response letters.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Nicardipine HCl
Part D
$2.0M
−21%
943
What pharmacies pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
Nicardipine 20 mg capsule: $1.15 per unitGeneric · −2% in a year
How its trials ended
21 ClinicalTrials.gov studies testing it, classified by TrialPanorama, partly automatically, so some labels are wrong
Of the 6 whose ending is known, 50% met their primary endpoint, 0% missed it and 50% stopped early.
Completed, result not reported943%Completed, result not reportedCount9Share43%
Met its primary endpoint314%Met its primary endpointCount3Share14%
Ongoing314%OngoingCount3Share14%
Status unknown314%Status unknownCount3Share14%
Stopped: sponsor or business decision210%Stopped: sponsor or business decisionCount2Share10%
Stopped: other or unclear15%Stopped: other or unclearCount1Share5%
Adverse event reports (FAERS)
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA